Clinical Trial Update: FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing hepatic arterial infusion FOLFOX plus irinotecan with or without bevacizumab to systemic FOLFOXIRI with or without bevacizumab in init…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Liver Metastases

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: RECRUITING